Consequences of the diabetic status on the oxidant/antioxidant balance

Diabetes and Metabolism

Volumn 26, Issue 3, 2000, Pages 163-176

  Bonnefont Rousselot, D ^a,b   Bastard, J P ^c   Jaudon, M C ^a   Delattre, J ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UFR Sci Pharmaceutiques Biologiques ^*  (France)

^c HÔPITAL TENON   (France)

Author keywords

Antioxidants; Diabetes; Glycation; Lipid peroxidation; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANTIOXIDANT; ASCORBIC ACID; DNA; FREE RADICAL; GLUCOSE; LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; OXIDIZING AGENT; POLYOL; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID;

ANTIOXIDANT ACTIVITY; APOPTOSIS; DIABETES MELLITUS; EXTRACELLULAR MATRIX; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; GLYCATION; HUMAN; INSULIN RESISTANCE; LIPID PEROXIDATION; MACROMOLECULE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; REVIEW;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; LIPID PEROXIDATION; OXIDANTS; OXIDATIVE STRESS;

EID: 0033937272     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (189)

1. Hayoz D, Ziegler T, Brunner HR, Ruiz J. Diabetes mellitus and vascular lesions. Metabolism, 1998, 47, 16-19.
2. Rösen P, Du X, Tschöpe D. Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention with a-tocopherol? Mol Cell Biochem, 1998, 188, 103-111.
3. Szaleczky E, Prechl J, Feher J, Somogyi A. Alterations in enzymatic antioxidant defence in diabetes mellitus - a rationale approach. Postgrad Med J, 1999, 75, 13-17.
4. Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA, 1994, 91, 7742-7746.
5. Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification in proteins in diabetic glomerular lesions. J Am Soc Nephrol, 1999, 10, 822-832.
6. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation producs in diabetic renal glomerular lesions. J Clin Invest, 1997, 100, 2995-3004.
7. e-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest, 1997, 99, 457-468.
8. Suzuki D, Miyata T. Carbonyl stress in the pathogenesis of diabetic nephropathy. Int Med, 1999, 38, 309-314.
9. e-(carboxymethyl)lysine independently of glycohaemoglobin concentrations. Diabetologia, 1999, 42, 603-607.
10. Giugliano D, Ceriello A. Oxidative stress and diabetic vascular complications. Diabetes Care, 1996, 19, 257-267.
11. Giardino I, Edelstein D, Brownlee M. Bcl-2 expression antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation end products in bovine endothelial cells. J Clin Invest, 1996, 97, 1422-1428.
12. Ceriello A, dello Russo P, Amstad P, Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture. Evidence linking hyperglycemia and oxidative stress. Diabetes, 1996, 45, 471-477.
13. Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J, 1988, 256, 205-212.
14. Hunt JV, Smith CCT, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes, 1990, 39, 1420-1424.
15. Gillery P, Monboisse JC, Maquart FX, Borel JP. Glycation of proteins as a source of superoxide. Diabetes Metab, 1988, 14, 25-30.
16. Sakurai T, Tsuchiya S. Superoxide production from non-enzymatically glycated proteins. FEBS Lett, 1988, 236, 406-410.
17. Ortwerth BJ, James H, Simpson G, Linetsky M. The generation of superoxide anions in glycation reactions with sugars, osones, and 3-deoxyosones. Biochem Biophys Res Commun, 1998, 245, 161-165.
18. Mossine VV, Linetsky M, Glinsky GV, Ortwerth BJ, Feather MS. Superoxide free radical generation by Amadori compounds: the role of acyclic forms and metal ions. Chem Res Toxicol, 1999, 12, 230-236.
19. Brownlee M, Cérami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. New Engl J Med, 1988, 318, 1315-1321.
20. Trivin F, Chevenne D, Hautecouverture M. Produits de Maillard et complications chroniques du diabète sucré. Ann Biol Clin, 1999, 57, 445-454.
21. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun, 1990, 173, 932-939.
22. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem, 1994, 269, 9889-9897.
23. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end product-induced activation of NFkB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes, 1997, 46, 1481-1490.
24. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes, 1991, 40, 405-412.
25. Myiata T, Inagi R, Asahi K, et al. Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and polyunsaturated fatty acids. FEBS Lett, 1998, 437, 24-28.
26. Saxena AK, Saxena P, Wu X, Obrenovich M, Weiss MF, Monnier VM. Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Biochem Biophys Res Commun. 1999, 260, 332-338.
27. Berg TJ, Clausen JT, Torjesen PA, Dahl-Jorgensen K, Bangstad HJ, Hanssen KF. The advanced glycation end product N epsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care, 1998, 21, 1997-2002.
28. Chellan P, Nagaraj RH. Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Arch Biochem Biophys, 1999, 368, 98-104.
29. Lederer MO, Klaiber RG. Cross-linking of proteins by Maillard processes: characterization and detection of lysine-arginine crosslinks derived from glyoxal and methylglyoxal. Bioorg Med Chem, 1999, 7, 2499-2507.
30. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J, 1999, 344, 109-116.
31. Oya T, Hattori N, Mizuno Y, et al. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem, 1999, 274, 18492-18502.
32. Paul RG, Bailey AJ. The effect of advanced glycation end-product formation upon cell-matrix interactions. Int J Biochem Cell Biol, 1999, 31, 653-660.
33. Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact, 1998, 111, 137-151.
34. Ranganathan S, Ciaccio PJ, Walsh ES, Tew KD. Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene, 1999, 240, 149-155.
35. Abordo EA, Minhas HS, Thornalley PJ. Accumulation of alpha-oxoaldehydes during oxidative stress: a role in cytotoxicity. Biochem Pharmacol, 1999, 58, 641-648.
36. Portero-Otin M, Pamplona R, Ruiz MC, Cabiscol E, Prat J, Bellmunt MJ. Diabetes induces an impairment in the proteolytic activity against oxidized proteins and a heterogeneous effect in nonenzymatic protein modification in the cytosol of rat liver and kidney. Diabetes, 1999, 48, 2215-2220.
37. Fujino T, Tada T, Beppu M, Kikugawa K. Purification and characterization of a serine protease in erythrocyte cytosol that is adherent to oxidized membranes and preferentially degrades proteins modified by oxidation and glycation. J Biochem, 1998, 124, 1077-1085.
38. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. Faseb J, 1999, 13, 23-30.
39. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med, 1994, 16, 383-391.
40. Greene DA, Stevens MJ. The sorbitol-osmotic and sorbitol redox hypotheses. In: Le Roith D, Taylor SI, Olefsky JM, eds. "Diabetes Mellitus". Philadelphia:Lippincott-Raven Publishers, 1996.
41. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest, 1991, 87, 432-438.
42. Corbett JA, McDaniel ML. Does nitric oxide mediate autoimmune destruction of beta-cells? Possible therapeutic interventions in IDDM. Diabetes, 1992, 41, 897-903.
43. Kolb H, Kolb-Bachofen V. Nitric oxide: a pathogenic factor in autoimmunity. Immunul Today, 1992, 13, 157-160.
44. Hamaoka R, Fujii J, Miyagawa J, et al. Overexpression of the aldosc reductase gene induces apoptosis in pancreatic beta-cells by causing a redox imbalance. J Biochem, 1999, 126, 41-47.
45. Hotta M, Tashiro F, Ikegami H, et al. Pancreatic beta-cell specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med, 1998, 188, 1445-1451.
46. Ceriello A. Oxidative stress and glycemic regulation. Metabolism, 2000, 49, 27-29.
47. Rudich A, Tirosh A, Potashnik R, Hemi R, Kannety H, Bashan N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes, 1998, 47, 1562-1569.
48. Tirosh A, Potashnik R, Bashan N, Rudich A. Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem, 1999, 274, 10595-10562.
49. 2 in tumor necrosis factor alpha-mediated insulin resistance. J Biol Chem, 1999, 274, 25078-25084.
50. Brown DM, Charonis AS, Furcht LT, et al. An overview of role of matrix components. Diabetes Care, 1991, 14, 157-159.
51. Gilbert RE, Cox A, Dziadek M, Cooper ME, Jerums G. Extracellular matrix and its interaction in the diabetic kidney: a molecular biological approach. J Diabetes Complications, 1995, 9, 252-254.
52. Krishnamurti U, Rondeau E, Sraer JD, Michael AF, Tsilibary EC. Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J Biol Chem, 1997, 272, 27966-27970.
53. Menon RP, Sudhakaran PR. Enhanced adhesion of human mononuclear cells to nonenzymatically glycosylated collagen I. Mol Cell Biochem, 1995, 148, 115-121.
54. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol, 1998, 44, 1013-1023.
55. Bendayan M. Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int, 1998, 54, 438-447.
56. Sajithlal GB, Chithra P, Chandrakasan G. Advanced glycation end products induce crosslinking of collagen in vitro. Biochim Biophys Acta, 1998, 1407, 215-224.
57. McAuliffe AV, Fischer EJ, McLennan SV, Yue DK, Turtle JR. High glucose inhibits effect of ascorbic acid on [35S] sulphate incorporation in mesangial cell and matrix proteoglycan. Diabetes Res Clin Pract. 1997, 37, 101-108.
58. Heffernan S, James V, Zilkens R, et al. Changes of extracellular matrix in a baboon (Papio hamadryas) model of insulin dependent diabetes: studies using electron microscopy and X-ray diffraction techniques. Diabetes Res Clin Pract, 1996, 34, 65-72.
59. Hoffman BB, Sharma K, Ziyadeh FN. Potential role of TGF-beta in diabetic nephropathy. Miner Electrolyte Metab, 1998, 24, 190-196.
60. Beaudeux JL, Guillausseau PJ, Peynet J, et al. Enhanced susceptibility of low-density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients. Clin Chim Acta, 1995, 239, 131-141.
61. Anderson JW, Gowri MS, Turner J, et al. Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabetes mellitus. J Am Coll Nutr, 1999, 18, 451-461.
62. Tan KC, Ai VH, Chow WS, Chau MT, Leong L, Lam KS. Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab, 1999, 84, 3212-3216.
63. Gugliucci A, Menini T, Stahl AJC. Susceptibility to copper-enhanced autoxidation of VLDL+LDL fractions from diabetic patients. Biochem Mol Biol Int, 1994, 32, 139-147.
64. Jenkins AJ, Klein RL, Chassereau CN, Hermayer KL, Lopes-Virella MF. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes, 1996, 45, 762-767.
65. Taus M, Ferretti G, Curatola G, Dousset N, Solera ML. Valdiguié P. Lower susceptibility of low density lipoprotein to in vitro oxidation in diabetic patients. Biochem Int, 1992, 28, 835-842.
66. Picard S, Talussot C, Serusclat A, Ambrosio N, Berthezene F. Minimally oxidized LDL as estimated by a new method increase in plasma of type 2 diabetic patients with atherosclerosis or nephropathy. Diabetes Metab, 1996, 22, 25-30.
67. Jain SK, Mc Vie R, Jaramillo JJ, Chen Y. Hyperketonemia (acetoacetate) increases the oxidizability of LDL+VLDL in type I diabetic patients. Free Radic Biol Med, 1998, 24, 175-181.
68. Leonhardt W, Hanefeld M, Muller G, et al. Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjects. Clin Chim Acta, 1996, 254, 173-186.
69. Oranje WA, Rondas-Colbers GJ, Swennen GN, Jansen H. Wolffenbuttel BH. Lack of effect on LDL oxidation and antioxidant status after improvement of metabolic control in type 2 diabetes. Diabetes Care, 1999, 22, 2083-2084.
70. Carantoni M, Abbasi F, Warmerdam F, et al. Relationship between insulin resistance and partially oxidized LDL particles in healthy, nondiabetic volunteers. Arterioscler Thromb Vasc Biol, 1998, 18, 762-767.
71. Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest, 1994, 94, 771-778.
72. Galle J, Schneider R, Winner B, et al. Give-oxidized LDL impair endothelial function more potently than oxidized LDL: role of enhanced oxidative stress. Atherosclerosis, 1998, 138, 65-77.
73. Lyons TJ, Jenkins AJ. Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol, 1997, 8, 174-180.
74. Edwards IJ, Wagner JD, Litwak KN, Rudel LL, Cefalu WT. Glycation of plasma low density lipoproteins increases interaction with arterial proteoglycans. Diabetes Res Clin Pract, 1999, 46, 9-18.
75. Lopes-Virella MF, Virella G. Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes, 1996, 45, S40-S44.
76. Lopes-Virella MF, Virella G, Orchard TJ, et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol, 1999, 90, 165-172.
77. Bellomo G, Moggi E, Poli M, Agosta F, Bollati P, Finardi G. Autoantihodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes, 1995, 44, 60-66
78. ème Colloque International de Biologie Prospective de Pont-à-Mousson. Paris:John Libbey Eurotext, 1997, 197-203.
79. Dandona P, Thusu K, Cook S, et al. Oxidative damage to DNA in diabetes mellitus. Lancet, 1996, 347, 444-445.
80. Collins AR, Raslova K, Somorovska M, et al. DNA damage in diabetes: correlation with a clinical marker. Free Radic Biol Med, 1998, 25, 373-377.
81. Fukagawa NK, Li M, Liang P, Russell JC, Sobel BE, Absher PM. Aging and high concentrations of glucose potentiate injury to mitochondrial DNA. Free Radic Biol Med, 1999, 27, 1437-1443.
82. Lefevre G, Beljean-Leymarie M, Beyerle F, et al. Évaluation de la peroxydation lipidique par le dosage des substances réagissant avec l'acide thiobarbiturique. Ann Biol Clin, 1998, 56, 305-319.
83. Gallou G, Ruelland A, Campion L, et al. Increase in thiobarbituric acid reactive substances and vascular complications in type 2 diabetes mellitus. Diabetes Metab, 1994, 20, 258-264.
84. Griesmacher A, Kindhauser M, Andert SE, et al. Enhanced serum levels of thiobarbituric acid-reactive substances in diabetes mellitus. Am J Med, 1995, 98, 469-475.
85. Ruiz C, Alegria A, Barbera R, Farre R, Lagarda MJ. Lipid peroxidation and antioxidant enzyme activities in patients with type I diabetes mellitus. Scand J Clin Lab Invest, 1999, 59, 99-105.
86. Vijayalingam S, Parthiban A, Shanmugasundaram K, Mohan V. Abnormal antioxidant status in impaired glucose tolerance and noninsulin-dependent diabetes mellitus. Diabet Med, 1996, 13, 715-719.
87. Akkus I, Kalak S, Vural H, et al. Leukocyte lipid peroxidation, superoxide dismutase, glutathione peroxidase and serum and leukocyte vitamin C levels of patients with type II diabetes mellitus. Clin Chim Acta, 1996, 244, 221-227.
88. Santini SA, Marra G, Giardina B, et al. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes, 1997, 46, 1853-1858.
89. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes, 1995, 44, 1054-1058.
90. 2-like compounds formed during peroxidation of arachidonic acid by a mechanism independent of the cyclooxygenase pathway. Proc Natl Acad Sci USA, 1990, 87, 9383-9387.
91. 2α levels are elevated in individuals with NIDDM. FEBS Lett, 1995, 368, 225-229.
92. Laight DW, Desai KM, Gopaul NK, Anggard EE, Carrier MJ. F2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: effects of vitamin E. Eur J Pharmacol, 1999, 377, 89-92.
93. 2α in diabetes mellitus. Effects of tight metabolic control and vitamin E supplementation. Diabetes, 1997, 46 (suppl. 1), 113A.
94. Childs RE, Badsk WG. The steady-state kinetics of peroxidase with 2,2'-azino-di-(3-ethylbenzthiazoline-6-sulphonic acid) as chromogen. Biochem J, 1975, 145, 93-103.
95. Brasseur L, Thérond P, Legrand A. Pouvoir antioxydant total du plasma. Act Pharm Biol Clin, 1995, 8, 239-244.
96. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes, 1994, 43, 1010-1014.
97. Cerellio A, Bortololti N, Pirisi M, et al. Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients. Diabetes Care, 1997, 20, 1589-1593.
98. Maxwell SRJ, Thomason H, Sandler D, et al. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest, 1997, 27, 484-490.
99. Opara EC, Abdel-Rahman E, Soliman S, et al. Depletion of total antioxidant capacity in type 2 diabetes. Metabolism, 1999, 48, 1414-1417.
100. Cerellio A, Bortolotti N, Crescentini A, et al. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest, 1998, 28, 329-333.
101. Leinonen JS, Alho H, Harmoinen A, Lehtimaki T, Knip M. Unaltered antioxidant activity of plasma in subjects at increased risk for IDDM. Free Radic Res, 1998, 29, 159-164.
102. Tribe RM, Poston L. Oxidative stress and lipids in diabetes: a role in endothelium vasodilator dysfunction? Vasc Med, 1996, 1, 195-206.
103. Hughes K, Choo M, Kuperan P, Ong CN, AW TC. Cardiovascular risk factors in non-diabetic controls: a population-based survey among Asians in Singapore. Atherosclerosis, 1998, 136, 25-31.
104. Osterode W, Holler C, Ulberth F. Nutritional antioxidants, red cell membrane fluidity and blood viscosity in type 1 (insulin dependent) diabetes mellitus. Diabet Med, 1996, 13, 1044-1050.
105. Kunisaki M, Umeda F, Inoguchi T, Watanabe J, Nawata H. Effects of vitamin E administration in diabetes mellitus. Diabetes Res, 1990, 14, 37-42.
106. Caye-Vaugien C, Krernpf M, Lamarche P, Charbonnel B, Pieri J. Determination of alpha-tocopherol in plasma, platelets and eryhtrocytes of type I and type II diabetic patients by higher perfromance liquid chromatography. Int J Vitam Nutr Res, 1990, 60, 324-330.
107. Kagan VE, Serbinova EA, Forte T, Scita G, Packer L. Recycling of vitamin E in human low density lipoproteins. J Lipid Res, 1992, 33, 385-397.
108. Asayama K, Uchida N, Nakane T, et al. Antioxidants in serum of children with insulin-dependent diabetes mellitus. Free Radic Biol Med, 1993, 15, 597-602.
109. Armstrong AM, Chestnutt JE, Gorley MJ, Young IS. The effect of dietary treatment on lipid peroxidation and antioxidant status in newly diagnosed non-insulin dependent diabetes. Free Radic Biol Med, 1996, 21, 719-726.
110. Rema M, Mohan V, Bhaskar A, Shanmugasundaram KR. Does oxidant stress play a role in diabetic retinopathy? Indian J Ophtalmol, 1995, 43, 17-21.
111. Will JC, Byers T. Does diabetes mellitus increase the requirement for vitamin C? Nutr Rev, 1996, 54, 193-202.
112. Will JC, Ford ES, Bowman BA. Serum vitamin C concentrations and diabetes: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr, 1999, 70, 49-52.
113. Jain SK, Mc Vie R. Effect of glycemic control, race (white versus black) and duration of diabetes on reduced glutathione content in erythrocytes of diabetic patients. Metabolism, 1994, 43, 306-309.
114. Muruganandam A, Drouilard C, Thibert RJ, Cheung RM, Draisey TF, Mutus B. Glutathione metabolic enzyme activities in diabetic platelets as a function of glycemic control. Thromb Res, 1992, 67, 385-397.
115. Sjogren A, Floren CH, Nilsson A. Magnesium, potassium and zinc deficiency in subjects with type II diabetes mellitus. Acta Med Scand, 1988, 224, 461-466.
116. Raz I, Karsai D, Katz M. The influence of zinc supplementation on glucose homeostasis in NIDDM. Diabetes Res, 1989, 11, 73-79.
117. Raz I, Havivi E. Trace elements in blood cells of diabetic subjects. Diabetes Res, 1989, 10, 21-24.
118. Faure P, Roussel A, Coudray C, Richard MJ, Halimi S, Favier A. Zinc and insulin sensitivity. Biol Trace Elem Res, 1992, 32, 305-310.
119. Faure P, Corticelli P, Richard MJ, et al. Lipid peroxidation and trace element status in diabetic ketotic patients: influence of insulin therapy. Clin Chem, 1993, 39, 789-793.
120. Blostein-Fujii A, DiSilvestro RA, Frid D, Katz C, Malarkey W. Short-term zinc supplementation in women with non-insulin-dependent diabetes mellitus: effects on plasma 5'-nucleotidase activities, insulin-like growth factor I concentrations, and lipoprotein oxidation rates in vitro. Am J Clin Nutr, 1997, 66, 639-642.
121. Haglund B, Ryckenberg K, Selinus O, Dahlquist G. Evidence of a relationship between childhood-onset type I diabetes and low groundwater concentration of zinc. Diabetes Care, 1996, 19, 873-875.
122. Faure P, Benhamou PY, Perard A, Halimi S, Roussel AM. Lipid peroxidation in insulin-dependent diabetic patients with early retina degenerative lesions: effects of an oral zinc supplementation. Eur J Clin Nutr, 1995, 49, 282-288.
123. Zargar AH, Shah NA, Masoodi SR, et al. Copper, zinc, and magnesium levels in non-insulin dependent diabetes mellitus. Postgrad Med J, 1998, 74, 665-668.
124. Ruiz C, Alegria A, Barbera R, Farre R, Lagarda J. Selenium, zinc and copper in plasma of patients with type 1 diabetes mellitus in different metabolic states. J Trace Elem Med Biol, 1998, 12, 91-95.
125. Thompson KH, Godin DV, Lee M. Tissue antioxidant status in streptozotocin-induced diabetes in rats. Effects of dietary manganese deficiency. Biol Trace Elem Res, 1992, 35, 213-224.
126. El-Yazigi A, Hannan N, Raines DA. Urinary excretion of chromium, copper, and manganese in diabetes mellitus and associated disorders. Diabetes Res, 1991, 18, 129-134.
127. Nuvarro-Alarcon M, Lopez-G de la Serrana H, Perez-Valero V, Lopez-Martinez C. Serum and urine selenium concentrations as indicators of body status in patients with diabetes mellitus. Sci Total Environ. 1999, 228, 79-85.
128. Battell ML, Delgatty HL, McNeill JH. Sodium selenate corrects glucose tolerance and heart function in STZ diabetic rats. Mol Cell Biochem, 1998, 179, 27-34.
129. Douillet C, Bost M, Accominotti M, Borson-Chazot F, Ciavatti M. Effect of selenium and vitamin E supplements on tissue lipids. peroxides, and fatty acid distribution in experimental diabetes. Lipids, 1998, 33, 393-399.
130. Douillet C, Bost M, Accominotti M, Borson-Chazot F, Ciavatti M. In vitro and in vivo effects of selenium and selenium with vitamin E on platelet functions in diabetic rats. Relationship to platelet sorbitol and fatty acid distribution. Biol Truce Elem Res, 1996, 55, 263-277.
131. Adachi T, Ohta H, Hayashi K, Hirano K, Marklund SL. The site of nonenzymic glycation of human extracellular-superoxide dismutase in vitro. Free Radic Biol Med, 1992, 13, 205-210.
132. Adachi T, Ohta H, Hirano K, Hayashi K, Marklund SL. Nonenzymic glycation of human extracellular superoxide dismutase. Biochem J, 1991, 279, 263-267.
133. Kawamura N, Ookawara T, Suzuki K, Konishi K, Mino M, Taniguchi N. Increased glycated Cu, Zn-superoxide dismutase levels in erythrocytes of patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1992, 74, 1352-1354.
134. Arai K, Iizuka S, Tada Y, Oikawa L, Taniguchi N. Increase in the glucosylated form of the erythrocyte Cu, Zn-superoxide dismutase in diabetes and close association of the non-enzymatic glucosylation with the enzyme activity. Biochim Biophys Acta, 1987, 924, 292-296.
135. Sakurai T, Matsuyama M, Tsuchiya S. Glycation of erythrocyte superoxide dismutase reduces its activity. Chem Pharm Bull, 1987, 35, 302-307.
136. Arai K, Maguchi S, Fujii S, Ishihashi H, Oikawa K, Taniguchi N. Glycation and inactivation of human Cu, Zn-superoxide dismutase. Identification of the in vitro glycated sites. J Biol Chem, 1987, 262, 16969-16972.
137. Yan H, Harding JJ. Glycation-induced inactivation and loss of antigenicity of catalase and superoxide dismutase. Biochem J, 1997, 328, 599-605.
138. Ookawara T, Kawamura N, Kitagawa Y, Taniguchi N. Site-specific and random fragmentation of Cu, Zn-superoxide dismutase by glycation reaction. Implication of reactive oxygen species. J Biol Chem, 1992, 267, 18505-18510.
139. Strange RC, Jones P, Bicknell J, Scarpello J. Expression of Cu, Zn-superoxide dismutase and glutathione peroxidase in erythrocytes from diabetic and non-diabetic subjects. Clin Chim Acta, 1992, 207, 261-263.
140. Cser A, Sziklai-Laszlo I, Menzel H, Lombek I. Selenium status and lipoproteins in healthy and diabetic children. J Trace Elem Electrolytes Health Dis, 1993, 7, 205-210.
141. Li W, Yanoff M, Jian B, He Z. Altered mRNA levels of antioxidant enzymes in pre-apoptotic pericytes from human diabetic retinas. Cell Mol Biol, 1999, 45, 59-66.
142. Uzel N, Sivas A, Uysal M, Oz H. Erythrocyte lipid peroxidation and glutathione peroxidase activities in patients with diabetes mellitus. Horm Metab Res, 1987, 19, 89-90.
143. Kowluru RA, Kern TS. Engerman RL. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system. Free Radic Biol Med, 1997, 22, 587-592.
144. Baldwin JS, Lee L, Leung TK, Muruganandam A, Mulus B. Identification of the site of non-enzymatic glycation of glutathione peroxidase: rationalization of the glycation-related catalytic alterations on the basis of three dimensional protein structure. Biochim Biophys Acta, 1995, 1247, 60-64.
145. Muruganandam A, Tannous M, Mutus B. ELISA for in vivo assessment of nonenzymatically glycated platelet glutathione peroxidase. Clin Biochem, 1994, 27, 293-298.
146. Wierusz-Wysocka B, Wysocki H, Byks H, Zozulinska D, Wykretowicz A, Kazmierczak M. Metabolic control quality and free radical activity in diabetic patients. Diabetes Res Clin Pract, 1995, 27, 193-197.
147. Sharma A, Kharb S, Chugh SN, Kakkar R, Singh GP. Evaluation of oxidative stress before and after control of glycemia and after vitamin E supplementation in diabetic patients. Metabolism, 2000, 49, 160-162.
148. Kinalski M, Sledziewski A, Telejko B, Zarzycki W, Kinalska I. Antioxidant therapy and streptozotocin-induced diabetes in pregnant rats. Acta Diabetol, 1999, A 113-117.
149. Vannucchi H, Araujo WF, Bernardes MM, Jordao Junior AA. Effect of different vitamin E levels on lipid peroxidation in streptozotocin-diabetic rats. Int J Vitam Nutr Res, 1999, 69, 250-254.
150. Jam SK, Mc Vie R, Jaramillo JJ, Palmer M, Smith T. Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type I diabetic patients. J Am Coll Nutr, 1996, 15, 458-461.
151. Paolisso G, d'Amore A, Galzerano D, et al. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care, 1993, 16, 1433-1437.
152. Jain SK, Mc Vie R, Jaramillo JJ, et al. Effects of modest vitamin E supplementation on lipid peroxidation products and other cardiovascular risk factors in diabetic patients. Lipids, 1996, 31, S87-S90.
153. Skrha J, Sindelka G, Kvasnicka J, Hilgertova J. Insulin action and fibrinolysis influenced by vitamin E in obese Type 2 diabetes mellitus. Diabetes Res Clin Pract, 1999, 44, 27-33.
154. Kaneto H, Kajimoto Y, Miyagavva J, et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes, 1999, 48, 2398-2406.
155. Chung TW, Hau Yu JJ, Liu DZ. Reducing lipid peroxidation stress of erythrocyte membrane by a-tocopherol nicotinate plays an important role in improving blood rheological properties in type 2 diabetic patients with retinopathy. Diabet Med, 1998, 15, 380-385.
156. Ziegler D, Hanefeld M, Ruhnau KJ, et al. and the Aladin Study group. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. Diabetologia, 1995, 38, 1425-1433.
157. Kennedy AL, Lyons TJ. Glycation. oxidation and lipoxidation in the development of diabetic complications. Metabolism, 1997, 46, 14-21.
158. Brownlee M. Glycation products and the pathocenesis of diabetic complications. Diabetes Care, 1992, 15, 1835-1843.
159. Nilsson BO. Biological effects of aminoguanidine: an update. Inflamm Res, 1999, 48, 509-515.
160. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science, 1986, 232, 1629-1632.
161. Jakus V, Hrnciarova M, Carsky J, Krahulec B, Rietbrock N. Inhibition of nonenzymatic protein glycation and lipid peroxidation by drugs with antioxidant activity. Life Sci, 1999, 65, 1991-1993.
162. Guillausseau PJ. Pharmacological prevention of diabetic microangiopathy: blocking the pathogenic mechanisms. Traitement préventif de la microangiopathie diabétique: bloquer les mécanismes pathogéniques. Diabetes Metab, 1994, 20, 219-228.
163. Youssef S, Nguyen DT, Soulis T, Panagiotopoulos S, Jerums G, Cooper ME. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int, 1999, 55, 907-916.
164. Corbett JA, Tilton RG, Chang K, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, fails to protect against insulitis and hyperglycemia induced by multiple low dose streptozotocin injections in mice. Autoimmunity, 1993, 15, 311-314.
165. Joly GA, Ayres M, Chelly F, Kilbourn RG. Effects of N-G-methyl-L-arginine, N-G-nitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun, 1994, 199, 147-154.
166. Philis-Tsimikas A, Parthasarathy S, Picard S, Palinski W, Witztum JL. Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Arterioscler Thromb Vasc Biol, 1995, 15, 367-376.
167. Picard S, Parthasarathy S, Fruebis J, Witztum JL. Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA, 1992, 89, 6876-6880.
168. •- produits par radiolyse continue de l'eau. J Chim Phys, 1997, 94, 283-288.
169. Courderot-Masuyer C, Dalloz F, Maupoil V, Rochette L. Antioxidant properties of aminoguanidine. Fundam Clin Pharmacol, 1999, 13, 535-540.
170. •- free radicals. Radiat Res 2000, 153, 497-507.
171. Giardino I, Fard AK, Hatchell DL, Browlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation and oxidant-induced
172. Ihm SH, Yoo HJ, Park SW, Ihm J. Effect of aminoguanidine on lipid peroxidation in steptozotocin-induced diabetic rats. Metabolism, 1999, 48, 1141-1145.
173. Kedziora-Komatowska KZ, Luciak M, Blaszczyk J, Pawlak W. Effect of aminoguanidine on erythrocyte lipid peroxidation and activities of antioxidant enzymes in experimental diabetes. Clin Chem Lab Med, 1998, 36, 771-775.
174. Friedman EA. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care, 1999, 22, B65-B71.
175. Freedman BI, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials, 1999, 20, 493-510.
176. Rahbar S, Kumar Yernini K, Scott S, Gonzales N, Lalezari I. Novel inhibitors of advanced glycation endproducts. Biochem Biophys Res Commun, 1999, 262, 651-656.
177. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun, 1999, 257, 251-258.
178. Faure P, Rossini E, Wiernsperger N, Richard MJ, Favier A, Halimi S. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes, 1999, 48, 353-357.
179. Ewis SA, Abdel-Rahman MS. Effect of metformin on glutathione and magnesium in normal and streptozotocin-induced diabetic rats. J Appl Toxicol, 1995, 15, 387-390.
180. Ewis SA, Abdel-Rahman MS. Influence of atenolol and/or metformin on glutathione and magnesium levels in diabetic rats. J Appl Toxicol, 1997, 17, 409-413.
181. Jyothirmayi GN, Soni BJ, Masurekar M, Lyons M, Regan TJ. Effects of metformin on collagen glycation and diastolic dysfunction in diabetic myocardium. J Cardiovasc Pharmacol Ther, 1998, 3, 319-326.
182. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol, 1999, 58, 1765-1773.
183. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes, 1999, 48, 198-202.
184. Tanaka Y, Uchino H, Shimizu T, et al. Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats. Eur J Pharmacol, 1999, 376, 17-22.
185. Yokoyama T, Yoshida Y, Inoue T, Horikoshi H. Inhibition of galactose-induced cataractogenesis by troglitazone, a new antidiabetic drug with an antioxidant property, in rat lens culture. J Ocul Pharmacol Ther, 1999, 15, 73-83.
186. Crawford RS, Mudaliar SR, Henry RR, Chait A. Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone. Diabetes, 1999, 48, 783-790.
187. Cominacini L, Garbin U, Pasini AF, et al. The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity. Cell Adhes Commun, 1999, 7, 223-231.
188. Renier G, Desfaits AC, Serri O. Gliclazide decreases low-density lipoprotein oxidation and monocyte adhesion to the endothelium. Metabolism, 2000, 49, 17-22.
189. Jennings PE, Belch JJ. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Metabolism, 2000, 49, 23-26.